黑色素瘤
药理学
化学
免疫疗法
活性氧
癌症研究
体内
免疫系统
医学
免疫学
生物化学
生物
生物技术
作者
Markus Burkard,Heike Niessner,Christian Leischner,Alban Piotrowsky,Olga Renner,Luigi Marongiu,Ulrich M. Lauer,Christian Busch,Tobias W. Sinnberg,Sascha Venturelli
出处
期刊:Cells
[Multidisciplinary Digital Publishing Institute]
日期:2023-01-07
卷期号:12 (2): 254-254
被引量:17
标识
DOI:10.3390/cells12020254
摘要
Ascorbate acts as a prooxidant when administered parenterally at high supraphysiological doses, which results in the generation of hydrogen peroxide in dependence on oxygen. Most cancer cells are susceptible to the emerging reactive oxygen species (ROS). Accordingly, we evaluated high-dose ascorbate for the treatment of the B16F10 melanoma model. To investigate the effects of ascorbate on the B16F10 cell line in vitro, viability, cellular impedance, and ROS production were analyzed. In vivo, C57BL/6NCrl mice were subcutaneously injected into the right flank with B16F10 cells and tumor-bearing mice were treated intraperitoneally with ascorbate (3 g/kg bodyweight), immunotherapy (anti-programmed cell death protein 1 (PD1) antibody J43; 2 mg/kg bodyweight), or both treatments combined. The efficacy and toxicity were analyzed by measuring the respective tumor sizes and mouse weights accompanied by histological analysis of the protein levels of proliferating cell nuclear antigen (Pcna), glucose transporter 1 (Glut-1), and CD3. Treatment of B16F10 melanoma-carrying mice with high-dose ascorbate yielded plasma levels in the pharmacologically effective range, and ascorbate showed efficacy as a monotherapy and when combined with PD1 inhibition. Our data suggest the applicability of ascorbate as an additional therapeutic agent that can be safely combined with immunotherapy and has the potential to potentiate anti-PD1-based immune checkpoint blockades.
科研通智能强力驱动
Strongly Powered by AbleSci AI